• 1
    Kitchener HC,Castle PE,Cox JT. Chapter 7: achievements and limitations of cervical cytology screening. Vaccine 2006; 24 ( Suppl 3): S63S70.
  • 2
    IARC. Cervix cancer screening, vol. 10. Lyon, France: IARC Press, 2005.
  • 3
    Cuzick J,Clavel C,Petry KU,Meijer CJ,Hoyer H,Ratnam S,Szarewski A,Birembaut P,Kulasingam S,Sasieni P,Iftner T. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 10951101.
  • 4
    Arbyn M,Sasieni P,Meijer CJ,Clavel C,Koliopoulos G,Dillner J. Chapter 9: clinical applications of HPV testing—a summary of meta-analyses. Vaccine 2006; 24 ( Suppl 3): S7889.
  • 5
    Schiffman M,Castle PE,Jeronimo J,Rodriguez AC,Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890907.
  • 6
    Castle PE,Wheeler CM,Solomon D,Schiffman M,Peyton CL. Interlaboratory reliability of hybrid capture 2. Am J Clin Pathol 2004; 122: 23845.
  • 7
    Carozzi FM,Del Mistro A,Confortini M,Sani C,Puliti D,Trevisan R,De Marco L,Tos AG,Girlando S,Palma PD,Pellegrini A,Schiboni ML, et al. Reproducibility of HPV DNA testing by hybrid capture 2 in a screening setting. Am J Clin Pathol 2005; 124: 71621.
  • 8
    Mayrand MH,Duarte-Franco E,Rodrigues I,Walter SD,Hanley J,Ferenczy A,Ratnam S,Coutlee F,Franco EL. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357: 157988.
  • 9
    Naucler P,Ryd W,Tornberg S,Strand A,Wadell G,Elfgren K,Radberg T,Strander B,Forslund O,Hansson BG,Rylander E,Dillner J. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 158997.
  • 10
    Bulkmans N,Berkhof J,Rozendaal L,van KF,Boeke A,Bulk S,Voorhorst F,Verheijen R,van GK,Boon M,Ruitinga W,van BM, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 176472.
  • 11
    Wright TC,Jr,Massad LS,Dunton CJ,Spitzer M,Wilkinson EJ,Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007; 197: 34655.
  • 12
    Wright TC,Jr,Schiffman M,Solomon D,Cox JT,Garcia F,Goldie S,Hatch K,Noller KL,Roach N,Runowicz C,Saslow D. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004; 103: 3049.
  • 13
    Sherman ME,Lorincz AT,Scott DR,Wacholder S,Castle PE,Glass AG,Mielzynska-Lohnas I,Rush BB,Schiffman M. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003; 95: 4652.
  • 14
    Kjaer S,Hogdall E,Frederiksen K,Munk C,van den BA,Svare E,Meijer C,Lorincz A,Iftner T. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res 2006; 66: 106306.
  • 15
    Gage JC,Hanson VW,Abbey K,Dippery S,Gardner S,Kubota J,Schiffman M,Solomon D,Jeronimo J. Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol 2006; 108: 26472.
  • 16
    Jeronimo J,Schiffman M. Colposcopy at a crossroads. Am J Obstet Gynecol 2006; 195: 34953.
  • 17
    Pretorius RG,Zhang WH,Belinson JL,Huang MN,Wu LY,Zhang X,Qiao YL. Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol 2004; 191: 4304.
  • 18
    Herrero R,Castle PE,Schiffman M,Bratti MC,Hildesheim A,Morales J,Alfaro M,Sherman ME,Wacholder S,Chen S,Rodriguez AC,Burk RD. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005; 191: 1796807.
  • 19
    Schiffman M,Herrero R,Desalle R,Hildesheim A,Wacholder S,Cecilia RA,Bratti MC,Sherman ME,Morales J,Guillen D,Alfaro M,Hutchinson M, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005; 337: 7684.
  • 20
    Herrero R,Schiffman MH,Bratti C,Hildesheim A,Balmaceda I,Sherman ME,Greenberg M,Cardenas F,Gomez V,Helgesen K,Morales J,Hutchinson M, et al. Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Rev Panam Salud Publica 1997; 1: 36275.
  • 21
    Bratti MC,Rodriguez AC,Schiffman M,Hildesheim A,Morales J,Alfaro M,Guillen D,Hutchinson M,Sherman ME,Eklund C,Schussler J,Buckland J, et al. Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10 000 women in Guanacaste, Costa Rica [Descripcion de un estudio prospectivo de siete anos sobre la infeccion por el virus del papiloma humano y el cancer cervicouterino en 10 000 mujeres de Guanacaste, Costa Rica]. Rev Panam Salud Publica 2004; 15: 7589.
  • 22
    Castle PE,Schiffman M,Gravitt PE,Kendall H,Fishman S,Dong H,Hildesheim A,Herrero R,Bratti MC,Sherman ME,Lorincz A,Schussler JE, et al. Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol 2002; 68: 41723.
  • 23
    Qu W,Jiang G,Cruz Y,Chang CJ,Ho GY,Klein RS,Burk RD. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol 1997; 35: 130410.
  • 24
    de Sanjose S,Diaz M,Castellsague X,Clifford G,Bruni L,Munoz N,Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007; 7: 4539.
  • 25
    Smith JS,Lindsay L,Hoots B,Keys J,Franceschi S,Winer R,Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121: 62132.
  • 26
    Schiffman M,Rodriguez AC. Heterogeneity in CIN3 diagnosis. Lancet Oncol 2008; 9: 4046.
  • 27
    McCredie MR,Sharples KJ,Paul C,Baranyai J,Medley G,Jones RW,Skegg DC. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008; 9: 42534.
  • 28
    Herrero R,Hildesheim A,Bratti C,Sherman ME,Hutchinson M,Morales J,Balmaceda I,Greenberg MD,Alfaro M,Burk RD,Wacholder S,Plummer M, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000; 92: 46474.
  • 29
    Mosher WD,Chandra A,Jones J. Sexual behavior and selected health measures: men and women 15–44 years of age, United States, 2002. Adv Data 2005; 362: 155.
  • 30
    Smith HO,Padilla LA. Adenocarcinoma in situ of the cervix: sensitivity of detection by cervical smear: will cytologic screening for adenocarcinoma in situ reduce incidence rates for adenocarcinoma. Cancer 2002; 96: 31922.
  • 31
    Bray F,Carstensen B,Moller H,Zappa M,Zakelj MP,Lawrence G,Hakama M,Weiderpass E. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 2005; 14: 21919.
  • 32
    Wang SS,Sherman ME,Hildesheim A,Lacey JV,Jr,Devesa S. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976–2000. Cancer 2004; 100: 103544.
  • 33
    Ferreccio C,Bratti MC,Sherman ME,Herrero R,Wacholder S,Hildesheim A,Burk RD,Hutchinson M,Alfaro M,Greenberg MD,Morales J,Rodriguez AC, et al. A comparison of single and combined visual, cytologic, and virologic tests as screening strategies in a region at high risk of cervical cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 81523.
  • 34
    Arbyn M,Bergeron C,Klinkhamer P,Martin-Hirsch P,Siebers AG,Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 2008; 111: 16777.
  • 35
    Nanda K,McCrory DC,Myers ER,Bastian LA,Hasselblad V,Hickey JD,Matchar DB. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000; 132: 81019.
  • 36
    Castle PE,Hillier SL,Rabe LK,Hildesheim A,Herrero R,Bratti MC,Sherman ME,Burk RD,Rodriguez AC,Alfaro M,Hutchinson ML,Morales J, et al. An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). Cancer Epidemiol Biomarkers Prev 2001; 10: 10217.
  • 37
    Guido R,Schiffman M,Solomon D,Burke L. Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. Am J Obstet Gynecol 2003; 188: 14015.
  • 38
    Pretorius RG,Kim RJ,Belinson JL,Elson P,Qiao YL. Inflation of sensitivity of cervical cancer screening tests secondary to correlated error in colposcopy. J Low Genit Tract Dis 2006; 10: 59.
  • 39
    Kreimer AR,Guido RS,Solomon D,Schiffman M,Wacholder S,Jeronimo J,Wheeler CM,Castle PE. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol Biomarkers Prev 2006; 15: 90814.
  • 40
    Mitchell MF,Tortolero-Luna G,Cook E,Whittaker L,Rhodes-Morris H,Silva E. A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. Obstet Gynecol 1998; 92: 73744.
  • 41
    Alvarez RD,Helm CW,Edwards RP,Naumann RW,Partridge EE,Shingleton HM,McGee JA,Hall JB,Higgins RV,Malone JM,Jr. Prospective randomized trial of LLETZ versus laser ablation in patients with cervical intraepithelial neoplasia. Gynecol Oncol 1994; 52: 1759.
  • 42
    Arbyn M,Paraskevaidis E,Martin-Hirsch P,Prendiville W,Dillner J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN—an update of pooled evidence. Gynecol Oncol 2005; 99(3 Suppl ): S7S11.
  • 43
    Andrae B,Kemetli L,Sparen P,Silfverdal L,Strander B,Ryd W,Dillner J,Tornberg S. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst 2008; 100: 6229.
  • 44
    Cuzick J. Routine audit of large-scale cervical cancer screening programs. J Natl Cancer Inst 2008; 100: 6056.
  • 45
    Slater DN,Milner PC,Radley H. Audit of deaths from cervical cancer: proposal for an essential component of the National Screening Programme. J Clin Pathol 1994; 47: 278.
  • 46
    Sung HY,Kearney KA,Miller M,Kinney W,Sawaya GF,Hiatt RA. Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan. Cancer 2000; 88: 22839.
  • 47
    Leyden WA,Manos MM,Geiger AM,Weinmann S,Mouchawar J,Bischoff K,Yood MU,Gilbert J,Taplin SH. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst 2005; 97: 67583.
  • 48
    Nygard JF,Nygard M,Skare GB,Thoresen SO. Screening histories of women with CIN 2/3 compared with women diagnosed with invasive cervical cancer: a retrospective analysis of the Norwegian Coordinated Cervical Cancer Screening Program. Cancer Causes Control 2005; 16: 46374.
  • 49
    Qiao YL,Sellors JW,Eder PS,Bao YP,Lim JM,Zhao FH,Weigl B,Zhang WH,Peck RB,Li L,Chen F,Pan QJ, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008; 9: 92936.